Treatment and Prognosis of Hepatitis B Virus Concomitant with Alcoholism by Lin, Chih-Wen et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Treatment and Prognosis of Hepatitis B Virus
Concomitant with Alcoholism
Chih-Wen Lin, Chih-Che Lin and Sien-Sing Yang
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/66981
Provisional chapter
      
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited. 
Chih-Wen Lin, Chih-Che Lin and Sien-Sing 
Yang
Additional information is available at the end of the chapter
Abstract
Hepatitis B virus (HBV) infection is a global disease worldwide. The Asia-Pacific region 
has a high prevalence of viral hepatitis, and Taiwan is a region of high prevalence of 
chronic hepatitis B (CHB) with increasing alcoholic liver disease. We have investigated the 
prognosis and treatment of patients with concomitant hepatitis B virus (HBV) infection 
and alcoholism. The 10-year cumulative incidence of hepatocellular carcinoma (HCC) is 
much higher in patients with concomitant alcoholism and HBV infection than in those 
with alcoholism or HBV infection alone. Treatment with antiviral therapy and abstinence 
may be started in patients with decompensated cirrhosis and compensated cirrhosis with 
high HBV DNA. In pre-cirrhotic cases, treatment with antiviral therapy and abstinence 
may be started in patients with persistently elevated ALT levels and high HBV DNA, 
and significant fibrosis with minimal elevated or normal ALT levels and mild high HBV 
DNA. Treatment with antiviral therapy and abstinence reduces the incidence of HCC in 
patients with concomitant HBV infection and alcoholism. In conclusion, patients with 
concomitant HBV infection and alcoholism have high incidence of cirrhosis, HCC, and 
mortality. Treatment with antiviral therapy and abstinence may be started to reduce the 
incidence of cirrhosis, HCC, and mortality in these patients.
Keywords: chronic hepatitis B, hepatitis B virus DNA, nucleos(t)ides analogues, 
alcoholism, hepatocellular carcinoma, treatment, prognosis
1. Introduction
Hepatitis B virus (HBV) infection is a global disease, affecting approximately 350 million 
people worldwide [1]. The Asia-Pacific region has a high prevalence of viral hepatitis, and 
Taiwan is a region with high prevalence of chronic hepatitis B (CHB) [2]. It is particularly 
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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endemic in Taiwan, where the infection is usually acquired perinatally or in early child-
hood [2]. The morbidity and mortality associated with CHB are substantial in that 15% to 
approximately 40% of infected patients will develop serious sequels including persistent 
hepatitis, hepatic failure, liver cirrhosis and hepatocellular carcinoma (HCC) during their 
lifetime [2].
Alcohol-related morbidity and mortality represent a major public health issue worldwide 
[3, 4]. The United States National Institute on Alcohol Abuse and Alcoholism defines “heavy 
drinking” as consuming more than fourteen drinks per week for males and seven drinks per 
week for females. The risk threshold for developing alcohol-related liver disease is  consuming 
20–30 g of alcohol per day, and the development of cirrhosis occurs in 10–20% of those 
 consuming more than 80 g of alcohol daily [3]. The Asia-Pacific region has a high prevalence 
of viral hepatitis, and Taiwan is a region of high prevalence of chronic hepatitis B (CHB) with 
increasing alcoholic liver disease [5–7]. The affordability of alcohol and changes in life style 
and drinking behavior have the causes for the increase in cases of hospitalization for alcoholic 
liver disease [6].
In the animal model system, mice fed with ethanol have an increased serum hepatitis B 
surface antigen (HBsAg) by up to seven folds accompanied by an increased in viral DNA 
load [8]. In addition, these ethanol-fed mice have elevated expression of HBV surface, core, 
and X antigens in the liver, accompanied by an increase in HBV RNA levels. Chronic etha-
nol consumption is found to stimulate hepatitis B virus replication and gene expression 
in HBV transgenic mice [8]. Our recent study also reveals that patients with concomitant 
alcoholism and HBV infection have high percentages of hepatitis B viral load in clinics [9]. 
Moreover, the lipid composition of cellular membranes in lipid rafts is altered by alcohol 
exposure, and  alcohol exposure may thereby influences HBV infectivity [10]. Furthermore, 
alcohol can influence anti-HBV immunity, an effect involving the cellular membrane as 
well as the lipid rafts. HBV is known to interfere with the T-cell receptor (TCR) responsible 
for interacting and  recognizing foreign antigens, thereby preventing the initiation of an 
immune response. This results in a defective adaptive immune response during chronic 
HBV infection [8, 11]. Thus, alcohol can acts synergistically with HBV to limit antiviral 
immunity. Since the  adaptive immunity plays a key role in viral clearance, the conse-
quences of alcohol’s effects on the TCR of HBV infection are of high interest in the field of 
hepatology [12].
2. Epidemiology
HBV infection is a serious global health problem, with 2 billion people infected worldwide 
and 350 million suffering from chronic HBV infection. HBV infections result in 0.5–1.2 million 
deaths per year caused by chronic hepatitis, cirrhosis, and HCC. HBV-related end-stage liver 
disease or HCC is responsible for over 0.5–1 million deaths per year and currently represents 
5–10% of cases of liver transplantation. Morbidity and mortality in CHB are linked to persis-
tence of viral replication and evolution to cirrhosis and/or HCC [1, 2].
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In Taiwan, the introduction of universal vaccination of neonates in 1983–1985 has drastically 
decreased the prevalence of HBsAg in children below the age of 15 from 9.8 % in 1984 to 0.5 % 
in 2004 [13]. This is accompanied by a significant decrease in the incidence of infant fulminant 
hepatitis associated with chronic liver disease, mortality, and HCC [14, 15].
Alcohol is abused by more than 18 million adults in the United States. A daily consumption 
of alcohol exceeding 80 g for more than 10 years increases the risk for HCC by fivefold, while 
daily consumption of alcohol below 80 g is not significantly associated with an increased risk 
for HCC [3, 4]. The risk for HCC in decompensated alcoholic cirrhosis is close to 1% per year 
[3, 4]. Alcohol consumption is one of the top five causes of disease and disability in almost all 
European countries [16]. In the United States, about 50% of liver-related death is attributed by 
alcohol consumption, accounting for $3 billion annually loss, and is the third leading cause of 
preventable deaths in the U.S. [17]. It is estimated that alcohol is responsible for 5.9% of global 
mortality worldwide [18] and 2.5 million deaths per annual [19, 20].
3. Prognosis
Based on a large nationwide Risk Evaluation of Viral Load Elevation and Associated Liver 
Disease/Cancer-Hepatitis B Virus (REVEAL-HBV) study performed in Taiwan for CHB 
without alcoholism, detectable serum HBV DNA at study entry is demonstrated to be a sig-
nificant risk predictor of HCC in HBV patients [21–23]. Those with detectable HBsAg are at 
5- to 98-fold higher risk of developing HCC [24]. The seropositivity for HBeAg is also found 
associated with an increase in risk for HCC [25]. Compared to those who are seronega-
tive for HBsAg and HBeAg, the hazard ratio (HR) of developing HCC is about 10 and 60, 
respectively, for individuals with seropositivity for HBsAg and both HBsAg and HBeAg [25, 
26]. The serum level of HBV DNA is therefore a strong risk predictor of HCC [21], and it is 
also an important and independent risk factor for disease progression prognosis (including 
cirrhosis, risk of death, metastasis, and recurrence following surgery) in chronic hepatitis 
B [22]. Alcohol has a synergistic effect in increasing the risk of HCC incidence in HBsAg-
positive men [27].
In one of our study, 966 cirrhotic patients in Taiwan, consisting of 632 patients with HBV 
 infection, 132 patients with HBV infection and alcoholism, and 202 patients with alcoholism, 
are evaluated for HCC development [6]. We show that 15.8, 28.8 and 10.4% of the patients 
with HBV infection alone, concomitant HBV infection and alcoholism, and alcoholism 
alone,  respectively, are found to have newly developed HCC after a period of 10 years of 
follow-up. The 1-, 3-, 5-, and 10-year cumulative incidence of HCC is 1.2, 9.4, 18.4, and 39.8%, 
respectively, for patients with HBV infection alone; 3.1, 28.7, 36.8, and 52.8%, respectively, 
for patients with concomitant HBV infection and alcoholism; and 1.1, 6.1, 10.7, and 25.6%, 
respectively, for patients with alcoholism alone (Figure 1). The 10-year cumulative incidence 
of HCC is much higher in patients with concomitant alcoholism and HBV infection than in those 
with  alcoholism alone or HBV infection alone (52.8% vs. 25.6% vs. 39.8%, p < 0.001). The mean 
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follow-up period is 2.9, 5.2, and 3.9 years for patients with concomitant HBV infection and 
 alcoholism, alcoholism alone, and HBV infection alone, respectively. The annual incidence 
of HCC is 9.9, 2.1, and 4.1%, respectively, for patients with concomitant HBV infection and 
 alcoholism, alcoholism alone, and HBV infection alone. Our findings reveal that heavy 
 alcohol consumption significantly increases the risk of developing HCC in HBV-related 
cirrhotic patients [6].
The baseline serum HBV DNA level, antiviral nucleos(t)ide analogues [NA(s)] therapy, serum 
α-fetoprotein, daily amount of alcohol intake, and years of alcohol intake are also found to 
be significantly associated with the incidence of HCC by univariate analyses. In multivari-
ate logistic regression analyses, antiviral NUCs therapy (OR = 0.01) and baseline high serum 
HBV DNA levels (OR = 16.8) are significantly linked to a reduction in the incidence of HCC. 
In addition, the cumulative incidence of HCC during the follow-up period is significantly 
higher in patients with higher baseline serum HBV DNA levels than those with lower base-
line serum HBV DNA levels. Alcoholic cirrhotic patients with higher serum HBV DNA levels 
have higher incidence of HCC than those with lower serum HBV DNA levels, and increasing 
HBV DNA levels precipitates the progression of liver cirrhosis to HCC [6].
Figure  1. Cirrhotic patients with concomitant HBV infection and alcoholism have higher cumulative incidence of HCC 
than those with alcoholism alone or HVB infection alone.
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In another case-control and hospital-based study conducted in Italy, the relative risks of HCC 
for HBsAg and heavy alcohol intake are 11.4 and 4.6, respectively [28]. Positive synergisms 
between HBsAg positivity and heavy alcohol intake are reported, suggesting a stronger addi-
tive effect of viral infections and alcohol drinking on the risk of HCC. On the basis of popula-
tion attributable risks (AR), heavy alcohol intake seems to be the single most relevant cause 
of HCC in this area (AR: 45%) followed by HBV (AR: 22%) infection [28]. Similarly, another 
study by Sagnelli and colleagues has demonstrates that alcohol abuse can increase the risk of 
hepatitis B infection progressing to liver cirrhosis by threefold [29].
Furthermore, in another hospital-based, case-control study carried out in USA, the ORs for 
HCC based on multivariate analysis are 12.6, 4.5, and 4.3, respectively, for patients with 
HBsAg, heavy alcohol consumption (daily consumption of more than 80 mL of alcohol), and 
diabetes mellitus. Based on the additive model, synergistic interactions are observed between 
heavy alcohol consumption and diabetes mellitus (OR, 9.9) and chronic hepatitis virus infec-
tion (OR, 53.9). The significant synergy observed between heavy alcohol consumption, hepa-
titis virus infection, and diabetes mellitus may suggest the presence of a common pathway for 
hepatocarcinogenesis [30].
In another Taiwanese men prospective and community-based study carried out in the 
REVEAL-HBV study cohort over a period of 14 years, 20% of the patients are reported to be 
alcohol users [27]. Based on analyses adjusted for multivariable, alcohol abuse and extreme 
obesity (BMI ≥30 kg/m2) have synergistic effects on the risk of incident HCC (HR, 3.40). 
Obesity and alcohol are also reported to have synergistic effects in increasing risk of incident 
HCC in HBsAg-positive men [27]. It is therefore concluded that lifestyle interventions might 
significantly reduce the incidence of HCC [27].
4. Treatment in patients with concomitant HBV infection and alcoholism
Antiviral therapies including lamivudine, adefovir dipivoxil, entecavir, telbivudine, tenofovir, 
and Peg-interferon have been widely prescribed for the treatment of HBV-related liver diseases 
worldwide [14, 31, 32]. Several large population-based and international studies have reveal that 
antiviral therapy could reduce the incidence of hepatic failure, cirrhosis, HCC, and mortality in 
CHB patients without alcoholism [33–40].
In patients with concomitant HBV infection and alcoholism, the prescription of both antiviral 
therapy and abstinence is important for the treatment of disease progression. Oral NA(s) can 
reduce the disease progression for HBV infection-induced liver diseases. Abstinence is one of 
the most important therapies for patients with alcohol-induced liver diseases [41]. In addi-
tion, abstinence has been shown to improve the histological features of hepatic injury and 
reduce the outcome of disease progression to cirrhosis, HCC, and mortality in patients with 
alcoholic liver diseases [5, 6, 41–45].
The indications of treatment for patients with concomitant HBV infection and alcoholism 
are based on three criteria: severity of liver disease, serum HBV DNA levels, and serum ALT 
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Alcoholic patients with 
HBsAg positive
HBV DNA (IU/mL) ALT Treatment
Decompensated cirrhosis Detectable Any Treat with NA(s) and 
abstinence
Compensated cirrhosis >2000 Any Treat NA(s) and abstinence
Severe reactivation of  
chronic HBV
Detectable Elevated Treat with NA(s) or Peg-
interferon and abstinence 
immediately
Non-cirrhotic HBeAg-
positive chronic hepatitis B
>20,000 >2× ULN Observation for 3 months. 
Treat with NA(s) or Peg-
interferon and abstinence
1–2× ULN Monitor every 3 months
Treat with NA(s) or Peg-
interferon and abstinence 
if noninvasive tests suggest 
significant fibrosis
Persistently normal Monitor every 3 months
Treat with NA(s) or Peg-
interferon and abstinence 
if noninvasive tests suggest 
significant fibrosis
2000–20,000 Any ALT Monitor every 3 months. 
Assess fibrosis noninvasively. 
Monitor every 3 months
Treat with NA(s) and 
abstinence if noninvasive 
tests suggest evidence of 
significant fibrosis.
<2000 <ULN Monitor every 3 months
Treat with NA(s) or Peg-
interferon and abstinence 
if noninvasive tests suggest 
significant fibrosis
>ULN Monitor every 3 months
Treat with NA(s) or Peg-
interferon and abstinence 
if noninvasive tests suggest 
significant fibrosis
Undetectable Any ALT Treat with abstinence
Non-cirrhotic HBeAg-
negative chronic hepatitis B
>2000 >2× ULN Observation for 3 months. 
Treat with NA(s) or Peg-
interferon and abstinence
1–2× ULN Monitor every 3 months
Treat with NA(s) or Peg-
interferon and abstinence 
if noninvasive tests suggest 
significant fibrosis
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levels [14]. The treatment in patients with concomitant HBV infection and alcoholism is sum-
marized in Table 1.
4.1. In cirrhotic patients or patient with severe HBV reactivation with concomitant HBV 
infection and alcoholism
1. Alcoholic cirrhotic patients with decompensated cirrhosis and detectable HBV DNA 
require urgent antiviral treatment with NA(s) and abstinence [46, 47].
2. Alcoholic cirrhotic patients with compensated cirrhosis and HBV DNA >2000 IU/mL 
should be treated with NA(s) and abstinence.
3. Alcoholic patients with severe reactivation of HBV infection (the presence of high ALT, 
high bilirubin, INR more than 1.5 with impending or overt hepatic decompensation, and 
detectable HBV DNA) should be treated immediately with NA(s) and abstinence to pre-
vent the development or deterioration of hepatic decompensation.
4.2. In pre-cirrhotic patients with concomitant HBV infection and alcoholism
1. Patient have persistently elevated ALT levels >2 times the upper limit of normal (ULN) 
(at least 3 months between observations) and HBV DNA >20,000 IU/mL if HBeAg posi-
tive and >2000 IU/mL if HBeAg negative. Treatment with antiviral therapy [NA(s) or 
Peg-interferon] and abstinence may be started. A noninvasive method for the estimation 
of the extent fibrosis is useful in such patients. Antiviral therapy and abstinence prevent 
further progression of fibrosis and other complications of liver disease.
2. Patients have minimally elevated or normal ALT levels (at least 3 months between 
 observations) and HBV DNA >20,000 IU/mL if HBeAg positive and >2000 IU/mL if 
HBeAg negative, and a noninvasive method shows the presence of a significant  fibrosis. 
Alcoholic patients with 
HBsAg positive
HBV DNA (IU/mL) ALT Treatment
Persistently normal Monitor every 3 months
Treat with NA(s) or Peg-
interferon and abstinence 
if noninvasive tests suggest 
significant fibrosis
<2000 >ULN Monitor every 3 months
Treat with NA(s) or Peg-
interferon and abstinence 
if noninvasive tests suggest 
significant fibrosis
Undetectable Any Treat with abstinence
Table 1. Treatment indications for patients with concomitant HBV infection and alcoholism.
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Treatment with antiviral therapy [NA(s) or Peg-interferon] and abstinence may be 
started. Antiviral therapy and abstinence prevent further progression of fibrosis and 
other complications of liver disease.
3. Patients have persistently elevated, minimally elevated, or normal ALT levels or HBV 
DNA <20,000 IU/mL if HBeAg positive and <2000 IU/mL if HBeAg negative, and 
a  noninvasive method shows the presence of a significant fibrosis. Treatment with 
 antiviral therapy [NA(s) or Peg-interferon] and abstinence may be started. NA(s) and 
abstinence prevent further progression of fibrosis and other complications of liver 
disease.
4. Patients have normal or elevated ALT levels and undetectable HBV DNA. Treatment 
with abstinence may be started. Abstinence prevents further progression of fibrosis and 
other complications of liver disease.
Our previous study shows that oral antiviral therapy significantly reduces the incidence of 
HCC in alcoholic cirrhotic patients with concomitant HBV infection (Figure 2) [6]. Therefore, 
aggressive NA(s) therapy should be considered in patients with alcoholic cirrhosis and detect-
able serum HBV DNA, in order to reduce the incidence of HCC [6].
Figure 2. The cumulative incidence of HCC in cirrhotic patients with concomitant alcoholism and HBV infection is 
significantly reduced in patients receiving oral antiviral therapy.
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5. Conclusion
Patients with concomitant HBV infection and alcoholism have high incidence of cirrhosis, 
HCC, and mortality. Treatment with antiviral therapy and abstinence may be started with 
the aim to reduce the incidence of cirrhosis, HCC, and mortality in patients with concomitant 
HBV infection and alcoholism.
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